2025 PSPA Masterclass: Diagnosing PSP & CBD

2025 PSPA Masterclass: Diagnosing PSP & CBD

Join PSPA's free online masterclass learning more about diagnosing Progressive Supranuclear Palsy (PSP) and Corticobasal Degeneration (CBD)

By PSPA

Date and time

Wed, 25 Jun 2025 10:00 - 11:30 PDT

Location

Online

About this event

  • Event lasts 1 hour 30 minutes

Welcome to the 2025 PSPA Masterclass: Diagnosing Progressive Supranuclear Palsy (PSP) and Corticobasal Degeneration (CBD) event:


The UK charity, PSPA, is hosting a free online masterclass on 25 June 2025 to help enhance health professionals’ understanding of the conditions and to aid early diagnosis and access to appropriate care.

PSP & CBD are rare neurological conditions where 60% of people are initially misdiagnosed, with an accurate diagnosis on average taking three years to achieve.


Speaker:

Dr Boyd Ghosh, Consultant Neurologist, Wessex Neurological Centre, Southampton


Attending this free masterclass will help you to:

1. Identify the early clinical features of PSP & CBD, including both motor and non-motor symptoms.

2. Differentiate PSP & CBD from other neurodegenerative disorders, particularly Parkinson’s disease, Alzheimer’s disease, and other atypical parkinsonian syndromes.

3. Recognise the value of a multidisciplinary team approach, to aid earlier suspected diagnosis of PSP & CBD.


If you have any questions regarding this event or need further information, please email carol.amirghiasvand@pspassociation.org.uk

Dr Boyd Ghosh is currently a consultant neurologist in the Wessex Neurological Centre in Southampton and Salisbury hospitals as well as honorary teacher at the University of Southampton. In addition, Dr Ghosh is currently Treasurer for the British Neuropsychiatric Association and a Trustee for PSPA.

Dr Ghosh leads a specialist regional service for patients with atypical Parkinsonian syndromes, which includes PSP, MSA, CBD as well as mimics. This is a multidisciplinary clinic, collaborating with therapists in the community, ophthalmologists and the palliative care services.

He has previously assisted PSPA in care pathway development and advised on several of their guides for healthcare professionals. He is principal investigator for commercial and academic studies investigating PSP and other atypical Parkinsonian syndromes. He lectures and publishes on the subject and teaches for a national course – the Parkinson’s Masterclass.

Organised by